KURA ONCOLOGY, INC. Deferred Tax Assets, Valuation Allowance
KURA ONCOLOGY, INC. (KURA) had Deferred Tax Assets, Valuation Allowance of $363.89 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $363.89M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $278.86M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $224.18M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $176.33M.
| Period end | Deferred Tax Assets, Valuation Allowance | Deferred Tax Assets, Valuation Allowance as first filed |
|---|---|---|
| 2025-12-31 | $363.89M 10-K · filed 2026-03-05 | |
| 2024-12-31 | $278.86M 10-K · filed 2026-03-05 | |
| 2023-12-31 | $224.18M 10-K · filed 2025-02-28 | |
| 2022-12-31 | $176.33M 10-K · filed 2024-02-27 | |
| 2021-12-31 | $133.21M 10-K · filed 2023-02-23 | |
| 2020-12-31 | $92.52M 10-K · filed 2022-02-24 | |
| 2019-12-31 | $62.42M 10-K · filed 2021-02-24 | |
| 2018-12-31 | $43.60M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $25.85M 10-K · filed 2019-03-05 | |
| 2016-12-31 | $21.45M 10-K · filed 2018-03-12 | |
| 2015-12-31 | $10.31M 10-K · filed 2017-03-14 | |
| 2014-12-31 | $1.41M 10-K · filed 2016-03-17 | $69.60K 10-K · filed 2015-02-27 |
| 2013-12-31 | $59.10K 10-K · filed 2015-02-27 | |
| 2012-12-31 | $49.40K 10-K · filed 2014-03-31 | |
| 2011-12-31 | $40.20K 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |